GlassScriptPhysician profile
Ousama Dabbagh
NPI 1982644704
$4,214.48
in general payments reported to CMS, 2019-2025
27 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $914 · 2021: $786 · 2022: $631 · 2023: $359 · 2024: $412 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.86 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,508.55 | 2019-2025 | Trelegy Ellipta, Nucala |
| Actelion Pharmaceuticals US, INC. | $1,000.49 | 2019-2025 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $257.89 | 2023-2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $190.10 | 2019-2020 | |
| Insmed, INC. | $171.12 | 2020-2025 | Arikayce |
| Electromed, INC. | $135.13 | 2021-2023 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.28 | 2019-2020 | |
| United Therapeutics Corporation | $104.51 | 2021-2025 | Tyvaso |
| Pulmonx Corporation | $99.26 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Grifols USA, LLC | $78.01 | 2019-2024 | Xembify |
| Genentech USA, INC. | $60.41 | 2019-2020 | |
| Genzyme Corporation | $57.86 | 2021-2024 | |
| Resmed Corp | $57.06 | 2019-2021 | |
| Advanced Respiratory, INC | $39.78 | 2020-2021 | |
| Olympus America INC. | $39.77 | 2022-2024 | Single-Use Flexible Video Bronchoscope |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $34.11 | 2020-2025 | |
| Allergan, INC. | $33.56 | 2019-2020 | |
| Abbvie INC. | $30.71 | 2023-2024 | Teflaro |
| Novartis Pharmaceuticals Corporation | $29.93 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $22.42 | 2019-2020 | |
| Inogen, INC. | $21.99 | 2022 | |
| Pfizer INC. | $21.89 | 2023 | |
| Jazz Pharmaceuticals INC. | $20.76 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.29 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.13 | 2025 | Fasenra |
| Zoll Respicardia, INC. | $16.02 | 2023 | Remede System |
| Merit Medical Systems INC | $12.45 | 2024 | Aspira |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ousama Dabbagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.